Prostatectomy in factor XI (plasma thromboplastin antecedent) deficiency

Area of Science:

• Hematology
• Urology
• Genetics

Background:

• Factor XI deficiency is a rare inherited bleeding disorder.
• Prostatectomy is a common urological procedure.
• Managing bleeding risk in patients with factor XI deficiency requires careful consideration.

Purpose of the Study:

• To evaluate the perioperative management of patients with factor XI deficiency undergoing prostatectomy.
• To determine the efficacy of fresh frozen plasma (FFP) in preventing and managing bleeding during and after prostatectomy.
• To assess the need for routine screening of factor XI deficiency in specific populations undergoing urological surgery.

Main Methods:

• Retrospective review of 10 patients with factor XI deficiency who underwent prostatectomy.
• Analysis of FFP administration strategies: preoperative and intraoperative/postoperative.
• Comparison of outcomes based on FFP treatment protocols.

Main Results:

• Three patients underwent suprapubic prostatectomy and three underwent transurethral resection, all receiving preoperative FFP.
• Four patients received FFP only in response to intraoperative or postoperative bleeding.
• The abstract does not provide specific details on the outcomes or bleeding events for each group.

Conclusions:

• All patients with partial or severe factor XI deficiency should receive preoperative FFP.
• FFP should be administered for at least 10 to 14 days postoperatively.
• Screening for factor XI deficiency is recommended for Ashkenazi Jews undergoing urological operations, irrespective of a personal or family history of bleeding.